Nordic drugmaker Swedish Orphan Biovitrum (STO: SOBI) today confirmed that the company is in discussions with a private equity firm regarding a possible sale of its Partner Products business area.
The discussions may or may not lead to an agreement, the company stated.
Products in the business area exclude Kineret (anakinra) and Orfadin (nitisinone), which are SOBI’s’ two largest products in terms of revenue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze